Key result
TMVI emerges as a less invasive treatment for high-risk, surgery-ineligible patients with severe MR.
Transcatheter mitral valve implantation (TMVI) is emerging as a potential less invasive treatment option for elderly or high-risk patients with severe mitral regurgitation who are ineligible for surgery.
May offer an alternative for high-risk MR patients ineligible for surgery; leaves open the need for randomized data on durability and outcomes.
In the last year transcatheter mitral valve implantation (TMVI) has seen a major jump in development. This technique offers the potential to treat a great number of elderly and/or high-risk patients with severe mitral regurgitation (MR). Such patients are declined surgical intervention either because the institutional Heart Team considers the risk of intervention to exceed the potential benefit, or because the patients and their families believe the morbidity of mitral surgery to be excessive. The advent of a less invasive transcatheter treatment could, therefore, potentially appeal to both clinicians and patients alike. In this overview paper, we describe briefly these recent developments in TVMI technologies as an introduction to the dedicated TVMI technical device parade later in this supplement.
No takes yet. Share an insight, caveat, or question.
Mylotte et al. (2015) conducted a review in severe mitral regurgitation (MR). Transcatheter mitral valve implantation (TMVI) was evaluated. Transcatheter mitral valve implantation (TMVI) is a rapidly developing, less invasive treatment option for elderly or high-risk patients with severe mitral regurgitation who are ineligible for surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: